Results 271 to 279 of about 70,621 (279)

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

New England Journal of Medicine, 2012
Javier Cortes, Seock-Ah Im, Young-Hyuck Im   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2015
openaire   +2 more sources

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Nature Reviews Clinical Oncology, 2009
Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi   +2 more
exaly  

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Lancet, The, 2019
Karen McAdam, Luke Hughes-Davies, Richard Simcock   +2 more
exaly  

Paclitaxel/trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Osimertinib/Trastuzumab-deruxtecan/Trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2007
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2003
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2014
openaire   +1 more source